COVID-19患者抗凝治疗方案的荟萃分析
结果显示两组死亡风险和净不良临床事件风险相似,较高剂量抗凝降低血栓栓塞事件风险但增加大出血风险,不支持常规使用治疗剂量或中间剂量抗凝。
要点
- 较高剂量抗凝与预防剂量抗凝的死亡风险相似(RR 0.96,95%CI 0.79-1.16,P=0.66)。
- 较高剂量抗凝降低血栓栓塞事件风险(RR 0.63,95%CI 0.47-0.84,P=0.002)但增加大出血风险(RR 1.76,95%CI 1.19-2.62,P=0.005)。
- 无明确生存获益证据,不支持在COVID-19患者中常规使用治疗剂量或中间剂量抗凝。
核心结论
- 较高剂量抗凝相比预防剂量抗凝未降低死亡风险,且增加大出血风险,不支持常规使用治疗剂量或中间剂量抗凝。
主要发现
- 较高剂量与预防剂量抗凝的死亡风险相似(RR 0.96,95%CI 0.79-1.16,P=0.66)。
- 较高剂量与预防剂量抗凝的净不良临床事件风险相似(RR 0.87,95%CI 0.73-1.03,P=0.11)。
- 较高剂量抗凝降低血栓栓塞事件风险(RR 0.63,95%CI 0.47-0.84,P=0.002)。
- 较高剂量抗凝增加大出血风险(RR 1.76,95%CI 1.19-2.62,P=0.005)。
- 非危重患者(RR 0.87,95%CI 0.50-1.52,P=0.62)和危重患者(RR 1.04,95%CI 0.93-1.17,P=0.5)中较高剂量与预防剂量抗凝的死亡风险均无统计学显著差异。
关键数值与推荐
- 治疗剂量对比预防剂量抗凝的死亡风险相似(RR 0.92,95%CI 0.69-1.21,P=0.54)。
- 中间剂量对比预防剂量抗凝的死亡风险相似(RR 1.01,95%CI 0.63-1.61,P=0.98)。
- D-二聚体明显升高患者中较高剂量抗凝也未降低死亡风险(RR 0.86,95%CI 0.64-1.16,P=0.34)。
临床怎么用
- 临床不应仅因COVID-19诊断而常规升级至治疗剂量或中间剂量抗凝。
- 对血栓栓塞高危患者使用较高剂量抗凝时需权衡大出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronavirus disease 2019 (COVID-19) is associated with a hypercoagulable state. It has been hypothesized that higher-dose anticoagulation, including therapeutic-dose and intermediate-dose anticoagulation, is superior to prophylactic-dose anticoagulation in the treatment of COVID-19. This meta-analysis evaluated the efficacy and safety of higher-dose anticoagulation compared with prophylactic-dose anticoagulation in patients with COVID-19. Ten randomized controlled open-label trials with a total of 5,753 patients were included. The risk of death and net adverse clinical events (including death, thromboembolic events, and major bleeding) were similar between higher-dose and prophylactic-dose anticoagulation (risk ratio (RR) 0.96, 95% CI, 0.79-1.16, P = 0.66 and RR 0.87, 95% CI, 0.73-1.03, P = 0.11, respectively). Higher-dose anticoagulation, compared with prophylactic-dose anticoagulation, decreased the risk of thromboembolic events (RR 0.63, 95% CI, 0.47-0.84, P = 0.002) but increased the risk of major bleeding (RR 1.76, 95% CI, 1.19-2.62, P = 0.005). The risk of death showed no statistically significant difference between higher-dose anticoagulation and prophylactic-dose anticoagulation in noncritically ill patients (RR 0.87, 95% CI, 0.50-1.52, P = 0.62) and in critically ill patients with COVID-19 (RR 1.04, 95% CI, 0.93-1.17, P = 0.5). The risk of death was similar between therapeutic-dose vs. prophylactic-dose anticoagulation (RR 0.92, 95% CI 0.69-1.21, P = 0.54) and between intermediate-dose vs. prophylactic-dose anticoagulation (RR 1.01, 95% CI 0.63-1.61, P = 0.98). In patients with markedly increased d-dimer levels, higher-dose anticoagulation was also not associated with a decreased risk of death as compared with prophylactic-dose anticoagulation (RR 0.86, 95% CI, 0.64-1.16, P = 0.34). Without any clear evidence of survival benefit, these findings do not support the routine use of therapeutic-dose or intermediate-dose anticoagulation in critically or noncritically ill patients with COVID-19.
引用
- Jorda A, Siller-Matula JM, Zeitlinger M, et al. Anticoagulant Treatment Regimens in Patients With Covid-19: A Meta-Analysis. Clin Pharmacol Ther. 2021. PMID: 34862791. doi:10.1002/cpt.2504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。